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In this chapter, we utilized lipid-modified-DNA UU11mer featuring two hydrophobic 
alkyl chains as a solubilizer of budesonide at a high loading capacity. The inhibition 


























This chapter will be submitted for publication: 
Y. Liu, H. Maarsingh, I. S. T. Bos, T. A. Oenema, H. Meurs, A. K. H. Hirsch, in preparation. 
Lipid-Modified-DNA Based Delivery System for Budesonide 
60 
 
4.1 Introduction  
Asthma,
[1]





) and rheumatoid arthritis
[4] 
are distinct disorders that are all 
characterized by chronic inflammation. The etiology of these diseases is not yet fully 
understood, but a complex interaction of environmental and genetic factors has been 
identified to contribute to pathogenesis.
[5]
As these diseases are incurable, the aim of 
current treatment is directed toward relieving disease symptoms.
[6] 
Different 
anti-inflammatory regimens exist for the different disease states, yet, 
anti-inflammatory glucocorticosteroids are used in all. 
Budesonide is a glucocorticoid with high anti-inflammatory activity that is 
commonly used for the treatment of these diseases by controlling the expression of 
pro-inflammatory cytokines. Depending on the disease that is treated, the delivery 











Hence, various delivery strategies have been developed for the various 
delivery routes.
[12] 
Because of its hydrophobicity and poor water-solubility,
[13] 
which 
require organic solvents like DMSO for in vitro studies, budesonide presents low local 
bioavailability during treatment. As a result, higher doses have to be utilized, 
increasing the risk of systemic adverse effects.
[14] 
Systemic bioavailability of oral 
budesonide is only 10–15% due to extensive first-pass metabolism, which limits the 
therapeutic potential of this efficacious glucucorticosteroid. In order to maximize drug 
efficacy and reduce the adverse effects, new delivery systems and delivery strategies 
are necessary.  
Micelles have specific properties such as high efficiency, good reproducibility, 
simple preparation and stimuli-responsive possibilities,
[15] 
making them widely used 
nanocarriers of poorly water-soluble drugs. Amphiphilic molecules consist of a 
hydrophilic and a hydrophobic moiety and can self-assemble into micelles in aqueous 
solution. Micelles have a hydrophilic external corona, and a hydrophobic interior in 
which hydrophobic drugs can be encapsulated through non-covalent interactions with 
minimal impact on the drug. 
Despite various amphiphilic materials being used,
[16] 
it is still a challenge to 
construct a biocompatible and effective micellar drug-delivery system. Previous 
studies have shown that lipid-modified-DNA amphiphiles, consisting of a hydrophilic 
DNA moiety and hydrophobic alkyl tails, can undergo self-assembly into micelles, 
leading to potential nanocarriers of hydrophobic drugs.
[17]
 Attributed to their small 
size and the use of biocompatible DNA as a component, these nanocarriers provide 




area to volume ratio; (2) improved biocompatibility by reducing the dose; (3) 
automated synthesis;
[18] 
and (4) ease of modification by taking advantage of DNA 
hybridization to endow ligand-receptor-mediated drug targeting properties (such as 
folic acid to sites of inflammation
[19]
). These advantages can be of benefit to almost 
all drug administration routes. 
Based on the above considerations, the aim of this study is to investigate a 
lipid-modified-DNA amphiphile (Figure 1c) that forms micelles at comparatively low 
critical micelle concentration (CMC) as solubilizers of budesonide (Figure 1a) and to 
test the anti-inflammatory properties of the novel form of solubilized budesonide. 
Herein, we report that lipid-modified-DNA, UU11mer (Figure 1b), featuring two 
hydrophobic alkyl chains (Figure 1d), lead to a new drug delivery system of 
budesonide (Figure 1a) that is stable and solubilizes budesonide with a high drug 






























Figure 1. Representation of a) budesonide; b) 5-(dodec-1-ynyl)uracil 
deoxyribophosphoramidite used in solid-phase synthesis of UU11mer; c) 11mer; d) 
UU11mer. 
 
4.2 Results and Disscussion 
4.2.1 Characterization of budesonide loaded lipid-modified-DNA micelles 
In the different protocols, a pristine DNA, 11mer (5’-TTTGGCGTCTT-3’) (Figure 
1c), that has the same nucleic acid sequence as UU11mer (5’-UUTGGCGTCTT-3’), 
was used as reference. UU11mer which contains two modified uracil bases (Figure 
1b), where U represents the modified uracil base) was synthesized by using the 
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modified 5-(dodec-1-ynyl)uracil phosphoramidite 2 (Figure 1b) during the standard 
solid-phase synthesis. The critical micelle concentration (CMC) was determined to be 
29 µM for UU11mer. Therefore, a concentration of 50 µM was chosen for the 
solubilization experiment because this concentration is greater than the CMC of 
UU11mer. Cryo-TEM was used to visualize the empty and loaded UU11mer micelles 
and to corroborate their sizes and morphological aspects. Cryo-TEM images (Figure 2) 
showed the formation of micelles with a narrow size distribution and regular shape 
both before and after budesonide loading. No obvious aggregation was visible and the 
diameters of UU11mer micelles increased slightly from 9.0 ± 1.2 nm to 10.3 ± 1.5 nm 
after budesonide loading. Various methods have been reported for producing delivery 
systems of water-insoluble drugs.
[20] 
In our research, budesonide was successfully 
incorporated into lipid-modified-DNA micelles by simply mixing the solid 
budesonide with aqueous solution of the carrier together and stirring for 12 h at room 
temperature. In this way, the budesonide was incorporated gradually into the micelles 
to reach the maximum LC and equilibrium. As a result, the LC of UU11mer was not 
exceeded as happened in some other loading method
[21]
, and the new solution was 




Figure 2. Cryo-TEM images of (a) UU11mer micelles; (b) UU11mer micelles loaded 
with budesonide. No stain was used and image acquisition was achieved at a 2 μm 







The loaded concentration of budesonide in H2O, 11mer micelles and UU11mer 
micelles, were determined by reversed-phase high-performance liquid 
chromatography (RP-HPLC, Figure 3) and calculated according to the calibration 
curve (Figure 4). The solubilization of budesonide into H2O, 11mer was performed as 
the same procedure as that into UU11mer UU11mer micelles. The solubility of 
budesonide was found to be 44.9 µM in H2O and 47.4 µM in 11mer aqueous solution 
(50µM), respectively (Table 1), the slight difference indicated that the usage of 
pristine oligonucleotide did not obviously improve the solubility of budesonide. 
However, the loaded concentration of budesonide into UU11mer micelles (94.5 µM) 
was much greater than that in 11mer, which illustrated that the formation of micelles 
greatly improved the solubility of budesonide in aqueous solution. In conclusion, 
BUDESONIDE was loaded into UU11mer micelles at an improved concentration and 
a high LC (22.4%), and a new stable delivery system of budesonide was generated. 
 
 
Figure 3. RP-HPLC spectra of a) budesonide solubilized in H2O; b) budesonide 
solubilized in 11mer aqueous solution; c) budesonide solubilized in UU11mer 
micelles aqueous solution. All experiments were performed in triplicate. 
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Table 1. Concentrations and drug LCs of budesonide loaded samples. 






LC (%) reference 
correction 







- H2O-2 630855 44.8 
H2O-3 629421 44.7 







- 11mer-2 670065 47.1 
11mer-3 664594 47.4 







10.1 UU11mer -2 1387306 96.9 
UU11mer -3 1391454 97.2 
 
 
Figure 4. Calibration curve of budesonide obtained by RP-HPLC. 
 
4.2.1 Anti-inflammatory activity of the new delivery system 
The anti-inflammatory activity of the different delivery system of budesonide was 
evaluated by studying its effect on interleukin (IL)-1β-induced release of IL-8 from 
hTERT immortalized human airway smooth muscle cells (Figure 5). In this setting, 
the effect of budesonide (3 nM, 30 nM and 300 nM) loaded UU11mer micelles was 
compared to the effect of 30 nM budesonide in DMSO on basal and IL-1β-induced 
IL-8 release. Basal IL-8 release, without IL-1β stimulation, was not affected by any of 
the budesonide solutions or vehicles used (Figure 5a). Stimulation with IL-1β induced 
a strong increase in the release of IL-8 from ASM (basal: 0.12 ng/mL vs. IL-1β: 188 




empty UU11mer micelles induced a 30% inhibition of the IL-1β response (p<0.01; 
Figure 5b), demonstrating that empty UU11mer micelles by themselves have some 
inhibitory effect on the IL-8 release. However, the reduction induced by the empty 
UU11mer micelles was not significantly different from the 22% reduction caused by 
DMSO. As expected, budesonide dissolved in DMSO at a concentration of 30 nM 
inhibited IL-1β induced IL-8 release by 78% (p<0.01, Figure 5b). Interestingly, 
budesonide solubilized using UU11mer micelles concentration-dependently inhibited 
IL-1β induced IL-8 release (Figure 5b). At concentrations of 3 nM, 30 nM and 300 
nM, the inhibition was 84.7% (p<0.01), 90.1% (p<0.001) and 92.2% (p<0.001), 
respectively. In addition, the inhibition with 3 nM using the UU11mer micelles is 
stronger than previously described using DMSO. In conclusion, the current study 
demonstrates that UU11mer micelles are an effective way to solubilize budesonide 
while maintaining the anti-inflammatory properties.  
 
 
Figure 5: IL-8 released by hTERT human ASM cells under basal (a) and IL-1β 
stimulated (b) conditions in the absence and presence of DMSO or UU11mer micelles 
alone or loaded with budesonide in indicated concentrations. Cells were pretreated 
with budesonide for 1 h and subsequently stimulated with concentration IL-1β for 24 
h. Supernatants were collected and IL-8 levels were analyzed by ELISA and corrected 








p<0.0001 compared to IL-1β-treated control; 
#
p<0.05 compared to DMSO; †p<0.01 and ‡p<0.001 compared to UU11mer. 
 
4.3 Conclusions 
In conclusion, we successfully incorporated the water-insoluble budesonide into 
biocompatible nanoparticles, lipid-modified-DNA (UU11mer) micelles. The new 
delivery system held at an improved concentration (up to 94.5 µM), a high drug LC 
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and good stability. The study on the inhibition of interleukin-8 release showed that in 
this new delivery system, budesonide maintained its anti-inflammatory activity. This 
new way to solubilize budesonide offers opportunities to formulate and administer 
budesonide in novel ways and would potentially allow for the treatment of additional 
conditions that are currently limited by the poor solubility and very low 
bioavailability of budesonide.   
 
4.4 Experimental section 
4.4.1 Materials and methods 
All chemicals were purchased from commercial suppliers and were used without 
further purification, unless otherwise noted. In all experiments, MilliQ standard water 
(Millipore Inc., USA) with a typical resistivity of 18.2MΩ/cm was used. Pristine 
oligonucleotide 11mer (5’-TTTGGCGTCTT-3’) was purchased from Biomers.net at 
HPLC purification grade. Lipid modified oligonucleotide (ODN) UU11mer 
(5’-UUTGGCGTCTT-3’) with two modified uracils (U represents the modified 
uracils) was prepared by using solid-phase synthesis. RP-HPLC conditions used: 
column, Xterra Prep MS C18, 10 µm, 7.8 x 150 mm; flow rate, 1.0 mL min
-1
; 
wavelength 244 nm; eluent A, H2O (0.1% TFA); eluent B, acetonitrile (0.1% TFA); 
injection volume, 20µL; gradient, table 2. 
 
Table 2. RP-HPLC gradient. 
Time (min) %A %B 
0 95 5 
3 95 5 
30 5 95 
35 5 95 
40 95 5 
 
4.4.2 Preparation of budesonide loaded lipid-modified-DNA micelles 
Budesonide 107.63 µg (0.25 µmol) in ethanol (1 mg/mL) was loaded into a 2.0 mL 
vial. ethanol is removed by vacumn at 30 
0
C for 3 h. In the mean time, UU11mer 
aqueous solution (50 µM) 1000 µL in 500 µL eppendorf tube was thermally cycled 
(90 °C, 30 min; -1 °C/2 min until room temperature) by using a polymerase chain 
reaction (PCR) thermocycler (Biorad, USA) before use. After that, UU11mer solution 




room temperature. Then the mixture was centrifugalized (10000 r/min) for 15 min and 
passed through a 0.22 µM pore-sized syringe filter (Milipore).  
 
4.4.3 Cryo-TEM 
Cyro-TEM was performed according to standard procedure. 3 µL of suspension 
was placed on a glow discharged holy carbon coated grid (Quantifiol 3.5/1) blotted 
and vitrified in a Vitrobot (FEI). Samples were observed in a Gatan 626 cryo-stage in 
a Philips CM 12 or CM120 operating at 120 keV or in a FEI Tecnai T20 operating at 
200 keV. Images were recorded under low-dose conditions on a slow-scan CCD 
camera. 
 
4.4.4 Determination of budesonide concentration and LC  
The concentration of budesonide in the dispersions was determined by RP-HPLC. 
The calibration curve of budesonide in ethanol was obtained by using the linear least 
square regression procedure of the peak area versus the concentration (Figure 4). Each 
measurement was performed in triplicate; the average value was used for calibration 
curve.  
To determine the concentration of budesonide in the micellar dispersions, 500 µL of 
the supernatant was lyophilized, and cold ethanol 500 µL was added to extract 
budesonide. After being centrifugated (10000 r/min) for 15 min and 300 µL 
supernatant was removed to run RP-HPLC measurement. Each measurement was 
performed in triplicate (Figure 3). And budesonide concentration was obtained 
according to the calibration curve. budesonide LC was calculated by equation S1: 
%LC = 
Weight of budesonide loaded
Weight of DNA 
 × 100%  (1) 
 
4.4.5 Cells 
Human bronchial smooth muscle cell lines, immortalized by stable expression of 
human telomerase reverse transcriptase (hTERT), were used for the IL-8 
determination experiments. hTERT airway smooth muscle cells were generated from 




4.4.6 Interleukin-8 determination 
Cells were plated in 24 wells cluster plates and grown to confluence, using DMEM 
supplemented with 10% foetal bovine serum and antibiotics (50 U/mL streptomycin, 
50 μg/mL penicillin and 1.5 μg/mL amphotericin B). Cultures were maintained in a 
humidified incubator at 37 
o 
C, gassed with 5% CO2. 
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Upon confluence, cells were washed two times with sterile phosphate-buffered 
saline (PBS) and serum starved for 24 h in DMEM supplemented with antibiotics and 
ITS (5 μg/mL insulin, 5 μg/mL transferrin, and 5 ng/mL selenium). Cells were then 
washed with PBS and stimulated with IL-1β (0.1 ng/mL) in serum free medium. 
UU11mer micelles loaded with budesonide (3 nM, 30 nM and 300 nM) were added 
30 min before stimulation with IL-1ß. Supernatants were collected 24 h after 
stimulation and stored at – 80 oC until use. 
IL-8 levels were determined using a specific sandwich enzyme-linked 
immunosorbent assay (ELISA) (Sanquin, Amsterdam, The Netherlands) according to 
the manufacturers’ instructions. 
 
4.5 Contributions from co-authors 
Prof. Dr. H. Maarsingh is acknowledged for providing the budesonide as a 
hydrophobic drug and for sharing his expertise on budesonide. The cell-based assays 
were performed by I. S. T. Bos and T. A. Oenema in the group of Prof. Dr. H. Meurs. 
Cyro-TEM measurements were done by Dr. M. C. A. Stuart. The lipid-modified DNA 





D. A. Edwards, A. Ben-Jebria, R. Langer, J. Appl. Physiol. 1998, 84, 379. 
[2]
  
D. C. Baumgart, W. J. Sandborn, Lancet 2012, 380, 1590. 
[3]
  
K. Conrad, D. Roggenbuck, M. W. Laass, Autoimmun. Rev. 2014, 13, 463. 
[4]
  
D. L. Scott, F. Wolfe, T. W. J. Huizinga, Lancet 2010, 376, 1094. 
[5]
  
a) R. K. Kumar, P. S. Foster, Immunol. Cell Biol. 2011, 79, 141; b) D. C. Baumgart, S. R. 
Carding, Lancet 2007, 369, 1627. 
[6]
  
a) C. A. Siegel, Dig. Dis. 2010, 28, 543; b) L. A. Macfarlane, D. J. Todd, Int. J. Rheum. Dis., 
2014, 17, 359; c) K. R. Murphy, M.D., J. Asthma, 2005, 42, 149 
[7]  K. Dahlström, S. Edsbäcker, A. Källén, Eur. J. Clin. Pharmacol. 1996, 49, 293. 
[8]
  
S. K. Gupta, J. M. Vitanza, M. H. Collins, Clin. Gastroenterol. Hepatol. 2015, 13, 66. 
[9] 
 
K. Nakamura, Y. Maitani, A. M. Lowman, K. Takayama, N. A. Peppas, T. Nagai, J. 
Controlled Release 1999, 61, 329. 
[10] G. D’Haens, L. Lemmens, K. Geboes, L. Vandeputte, F. V. Acker, L. Mortelmans, M. Peeters, 
S. Vermeire, F. Penninckx, F. Nevens, M. Hiele, P. Rutgeerts, Gastroenterology 2001, 120, 
1323. 
[11] C. Jacobs, R. H. Müller, Pharmacol. Rev. 2002, 19, 189. 
[12] a) Y. J. Oh, J. Lee, J. Y. Seo, T. Rhim, S.-H. Kim, H. J. Yoon, K. Y. Lee, J. Controlled Release 
2011, 150, 56; b) A. Amani, P. York, H. Chrystyn, B. J. Clark, AAPS PharmSciTech 2010, 11, 
1147; c) M. N. Sahib, Y. Darwis, K. K. Peh, S. A. Abdulameer, Y. T. F. Tan, Int. J. 
Nanomedicine 2011, 6, 2351.   
[13] H. S. M. Ali, P. York, N. Blagden, S. Soltanpour, W. E. Acree Jr., A. Jouyban, J. Chem. Eng. 




[14] R. Dahl, Resp. Med. 2006, 100, 1307. 
[15] a) Z. Ahmad, A. Shah, M. Siddiq, H.-B. Kraatz, RSC Adv. 2014, 4, 17028; b) K. Kataoka, A. 
Harada, Y. Nagasaki, Adv. Drug Deliv. Rev. 2012, 64, 37; c) Y. Lu, K. Park, Int. J. Pharm. 
2013, 453, 198; d) U. Kedar, P. Phutane, S. Shidhaye, V. Kadam, Nanomedicine 2010, 6, 714. 
[16] S. Movassaghian, O. M. Merkel, V. P. Torchilin, WIREs Nanomed. Nanobiotechnol. 2015, 7, 
691. 
[17] M. Anaya, M. Kwak, A. J. Musser, K. Müllen, A. Herrmann, Chem. Eur. J. 2010, 16, 12852. 
[18] a) L. Bellon, F. Wincott, Oligonucleotide Synthesis, 475-528, F. Albericio Ed., CRC Press 
2000; b) S. Kosuri, G. M. Church, Nat. Methods 2014, 11, 499. 
[19] P. S. Low, W. A. Henne, D. D. Doorneweerd, Acc. Chem. Res. 2008, 41, 120.  
[20] a) K. K. Jette, D. Law, E. Schmitt, G. S. Kwon, Pharmaceut. Res.2004, 21, 1184; b) K. 
Kataoka, A. Harada, Y. Nagasaki, Adv. Drug Deliv. Rev. 2001, 47, 113; c) N. El-Gendy, E. M. 
Groman, E. J. Munson, C. Berkland, J. Pharm. Sci. 2009, 98, 2731; d) E. Fournier, M.-H. 
Dufresne, D. C. Smith, M. Ranger, J.-C. Leroux, Pharmaceut. Res. 2004, 21, 962. 
[21]
 
J.-W. Hofman, M. G. Carstens, F. van Zeeland, C. Helwig, F. M. Flesch, W. E. Hennink, C. F. 
van Nostrum, Pharmaceut. Res. 2008, 25, 2065. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
